Sydnexis

Del Mar, CA · Founded 2014 · Medtech · Still private

Pharmaceutical therapeutic for pediatric progressive myopia to slow or halt disease progression in children's eyes

Claim this profile

Follows are private to you and power your alerts

Updated · sydnexis.com

Sector
Medtech
Headquarters
Del Mar, CA
Founded
2014
Latest Form D
$20M, Apr 2025
Total capital
$72.3M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$72.3M
4 Form D · last Apr 2025
18 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
20
20 pending · first 2016
Rank in peer group#1 of 29

Capital timeline

20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $72.3M1st Form D$5.5M2nd Form D$45.8M3rd Form D$1.0M4th Form D$20M
20172019202120232025FEDERAL ↑EQUITY ↓Cumulative $72.3M1st Form D$5.5M2nd Form D$45.8M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$20M
  • Private capital raisedForm D · SEC · 3rd filing$1.0M
  • Private capital raisedForm D · SEC · 2nd filing$45.8M
  • Private capital raisedForm D · SEC · 1st filing$5.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 29 peers

Line = median

Medtech · Molecule

  • Granted patents#1 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Greg K. GrunbergDirectorNamed in SEC Form D filings
  • Greg Jacqueline OstrowExecutive Officer, DirectorNamed in SEC Form D filings
  • Jeffry K. WeinhuffDirectorNamed in SEC Form D filings
  • Juliet BakkerDirectorNamed in SEC Form D filings
  • Kenneth Jacqueline WidderExecutive Officer, DirectorNamed in SEC Form D filings
  • Kevin Jacqueline JohnsonDirectorNamed in SEC Form D filings
Show all 13 people
  • Mary Jaqueline JohnsonExecutive OfficerNamed in SEC Form D filings
  • Patrick JohnsonExecutive Officer, PromoterNamed in SEC Form D filings
  • Perry Jaqueline SternbergExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Richard K. LindstromDirectorNamed in SEC Form D filings
  • Tyler K. StowaterDirectorNamed in SEC Form D filings
  • Zachary Jacqueline ScheinerDirectorNamed in SEC Form D filings
  • Zach ScheinerDirectorNamed in SEC Form D filings

What it has protected

USPTO · 20 granted of 40
  • PendingOphthalmic CompositionUSPTOApplication 19572547
  • GrantedOphthalmic CompositionUSPTOUS 12,629,360
  • PendingD2O Stabilized Pharmaceutical FormulationsUSPTOApplication 18915137
Show all 40 patent records
  • Ophthalmic CompositionJul 30, 2026 · Application 19572547Pending
  • Ophthalmic CompositionMay 19, 2026 · US 12,629,360Granted
  • D2O Stabilized Pharmaceutical FormulationsSep 4, 2025 · Application 18915137Pending
  • Ophthalmic CompositionAug 14, 2025 · Application 19196121Pending
  • Ophthalmic Composition And Delivery Device ThereofJun 12, 2025 · Application 18763381Pending
  • D2O Stabilized Pharmaceutical FormulationsDec 17, 2024 · US 12,168,017Granted
  • Ophthalmic CompositionDec 5, 2024 · Application 18784718Pending
  • D2O Stabilized Pharmaceutical FormulationsAug 27, 2024 · US 12,070,466Granted
  • Ophthalmic Compositions For PresbyopiaMay 2, 2024 · Application 18263952Pending
  • Ophthalmic CompositionFeb 13, 2024 · US 11,896,588Granted
  • Ophthalmic CompositionFeb 6, 2024 · US 11,890,277Granted
  • Ophthalmic CompositionJan 30, 2024 · US 11,883,390Granted
  • Ophthalmic Composition And Delivery Device ThereofNov 30, 2023 · Application 18363223Pending
  • Ophthalmic CompositionMar 7, 2023 · US 11,596,625Granted
  • Ophthalmic Compositions Comprising D2OFeb 9, 2023 · Application 17784841Pending
  • Ophthalmic CompositionDec 29, 2022 · Application 17894885Pending
  • Ophthalmic CompositionDec 29, 2022 · Application 17894884Pending
  • Ophthalmic CompositionDec 29, 2022 · Application 17894882Pending
  • Ophthalmic CompositionDec 1, 2022 · Application 17681560Pending
  • Ophthalmic CompositionAug 25, 2022 · Application 17721831Pending
  • Ophthalmic CompositionAug 25, 2022 · Application 17721838Pending
  • Ophthalmic CompositionJul 12, 2022 · US 11,382,909Granted
  • D2O Stabilized Pharmaceutical FormulationsJul 6, 2021 · US 11,052,095Granted
  • D20 Stabilized Pharmaceutical FormulationsJul 6, 2021 · US 11,052,094Granted
  • Ophthalmic CompositionMar 23, 2021 · US 10,953,002Granted
  • Ophthalmic CompositionMar 9, 2021 · US 10,940,145Granted
  • Ophthalmic CompositionJan 12, 2021 · US 10,888,557Granted
  • Ophthalmic CompositionDec 15, 2020 · US 10,864,208Granted
  • Ophthalmic CompositionNov 24, 2020 · US 10,842,787Granted
  • Ophthalmic Composition And Delivery Device ThereofNov 5, 2020 · Application 16765144Pending
  • Ophthalmic CompositionOct 29, 2020 · Application 16908426Pending
  • Ophthalmic CompositionOct 27, 2020 · US 10,813,923Granted
  • Ophthalmic CompositionOct 1, 2020 · Application 16785411Pending
  • Ophthalmic CompositionFeb 12, 2019 · US 10,201,534Granted
  • Ophthalmic CompositionSep 18, 2018 · US 10,076,515Granted
  • Ophthalmic CompositionSep 26, 2017 · US 9,770,447Granted
  • Ophthalmic CompositionAug 23, 2016 · US 9,421,199Granted
  • Ophthalmic CompositionJan 14, 2016 · Application 14859042Pending
  • Ophthalmic CompositionApplication 62096433Pending
  • Methods And Compositions For Increasing Pupil DilationApplication PCTUS2025022773Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .